Auxilium Pharmaceuticals, Inc. Appoints Adrian Adams Chief Executive Officer and President

Mr. Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as Chairman and CEO of Neurologix, Inc., a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system. Prior to that, he served as President and CEO of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co. Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. beginning in 2007 until its acquisition by Dainippon Sumitomo Pharma Co., Ltd in 2010. Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in 2006. Mr. Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).

"Adrian is an industry veteran with an excellent reputation for growing organizations, driving corporate development activities and successfully building pipelines to create value for shareholders," said Rolf Classon, Chairman of Auxilium's Board of Directors. "We believe that his visionary leadership and operational expertise will lead Auxilium to profitability and success as we seek to maximize the value of XIAFLEX® and Testim® while delivering on our current pipeline. We welcome Adrian to Auxilium and believe the Company can continue to build from its solid foundation and strong growth prospects."

"I am pleased to be joining Auxilium, a Company with a growing presence in specialty therapeutics, a talented workforce and well-established relationships with its business partners and customers," said Mr. Adams. "I look forward to working with the Board and the management team to strengthen the Company's financial and operational performance, drive the commercialization of the current and future pipeline and position Auxilium to achieve its full potential, creating value for shareholders."
Mr. Classon continued, "On behalf of Auxilium's Board of Directors and the entire Auxilium team, I want to thank Armando for his contributions over the past five years. He has been instrumental to the Company's continued progress, and we wish him the very best going forward."